Clinical Trial: A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer

U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07418931) titled 'A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer' on Feb. 04.

Brief Summary: This is a multicenter phase II study enrolling treatment- naive patients with metastatic or recurrent squamous carcinoma of the lung

Study Start Date: May, 2026

Study Type: INTERVENTIONAL

Condition: Advanced Squamous Non-Small Cell Lung Cancer

Intervention: DRUG: Cemiplimab 350 mg IV

Over approximately 30 min +/- 10 min. Day 1 every 21 days

DRUG: Paclitaxel 200 mg/sqm IV

Over approximately 180 min. Day 1 every 21 da...